Key Takeaways
- • MCM Capital Partners, a Cleveland-based micro-cap private equity firm, has acquired Octex, a Sarasota-based custom injection molder specializing in medical device and life sciences components.
- • Octex operates a 60,000 square-foot ISO 13485-certified manufacturing facility and owns Omnia Scientific, a wholly owned subsidiary providing CT scanning, dimensional inspection, and reverse engineering services to third-party customers.
- • The acquisition represents a direct sourcing effort by MCM, culminating from a relationship with Octex's ownership spanning back to 2016.
- • MCM plans to deploy capital toward business development, commercial infrastructure expansion, and strategic acquisitions to broaden Octex's technical capabilities and customer relationships.
- • Bobby Kingsbury, Managing Partner at MCM Capital, emphasized the firm's commitment to preserving Octex's established market differentiation while investing in capacity and talent to fuel growth.
Summary
MCM Capital Partners has completed its acquisition of Octex, marking a strategic entry into the specialized precision injection molding sector. Octex, based in Sarasota, Florida, manufactures highly engineered thermoplastic components for medical device, life sciences, and technically demanding industrial applications from its 60,000 square-foot manufacturing facility. The company holds ISO 13485 certification, a critical compliance standard for medical device suppliers, positioning it within a regulated and specialized market segment.
The target company's value proposition extends beyond its core injection molding operations. Through its wholly owned subsidiary, Omnia Scientific, Octex provides computed tomography scanning, dimensional inspection, and reverse engineering services. This ancillary business serves both Octex's internal manufacturing operations and a growing roster of third-party customers, creating a diversified revenue model within the precision manufacturing ecosystem.
The transaction reflects MCM Capital's long-term sourcing discipline. The acquisition resulted from a decade-long relationship between MCM's investment team and Octex's ownership, with initial facility tours and relationship-building occurring as far back as 2016. This extended evaluation period underscores a micro-cap private equity approach focused on deep market knowledge and relationship-driven deal sourcing rather than competitive auction processes.
MCM Capital's post-acquisition strategy centers on organic growth and selective consolidation. According to Bobby Kingsbury, Managing Partner at MCM Capital, the firm intends to invest in capacity expansion, deepen commercial infrastructure, and pursue strategic acquisitions to enhance Octex's technical capabilities and broaden its customer base. The capital infusion and operational support are positioned as additive to the existing management team and company culture, with the stated goal of honoring the market reputation and precision standards that Octex has built over decades.
This acquisition aligns with broader private equity interest in highly specialized manufacturing businesses serving regulated end-markets, where durable competitive advantages and customer relationships create stable, defensible returns.
The target company's value proposition extends beyond its core injection molding operations. Through its wholly owned subsidiary, Omnia Scientific, Octex provides computed tomography scanning, dimensional inspection, and reverse engineering services. This ancillary business serves both Octex's internal manufacturing operations and a growing roster of third-party customers, creating a diversified revenue model within the precision manufacturing ecosystem.
The transaction reflects MCM Capital's long-term sourcing discipline. The acquisition resulted from a decade-long relationship between MCM's investment team and Octex's ownership, with initial facility tours and relationship-building occurring as far back as 2016. This extended evaluation period underscores a micro-cap private equity approach focused on deep market knowledge and relationship-driven deal sourcing rather than competitive auction processes.
MCM Capital's post-acquisition strategy centers on organic growth and selective consolidation. According to Bobby Kingsbury, Managing Partner at MCM Capital, the firm intends to invest in capacity expansion, deepen commercial infrastructure, and pursue strategic acquisitions to enhance Octex's technical capabilities and broaden its customer base. The capital infusion and operational support are positioned as additive to the existing management team and company culture, with the stated goal of honoring the market reputation and precision standards that Octex has built over decades.
This acquisition aligns with broader private equity interest in highly specialized manufacturing businesses serving regulated end-markets, where durable competitive advantages and customer relationships create stable, defensible returns.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.